Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

Summary

A phase 2, open-label randomized, multicenter trial to compare CC-486 in combination with Abraxane administered weekly with respect to overall survival, objective tumor response rate and Progression-Free Survival (PFS) in participants diagnosed with metastatic malignant melanoma.

Timeline

Start

2014-01

Primary completion

2014-01

Completion

2014-01

Outcome

Outcome not reported

Stopped (Business): “Strategic decision not to proceed with the opening of this study. There are no concerns over the safety or quality of the investigational products involved.”

Drugs

Indications